灯盏生脉胶囊辅助治疗强直性脊柱炎临床研究

目的：观察灯盏生脉胶囊治疗强直性脊柱炎的疗效与安全性。方法：80例强直性脊柱炎（AS）患者随机分为两组,每组各40例,对照组及治疗组均常规给非甾体消炎药（NSAIDs）、慢作用抗风湿药物（DMARDs）口服,治疗组加服灯盏生脉胶囊0.36g/次,3次/d。两组均治疗12周,观察治疗前后症状、体征的变化。结果：终点总有效率治疗组为87.18%与对照组组的75.68%（P〈0.05）有显著差异,治疗12周后治疗组BASDAI、BASFI评分及ESR、CRP值分别为（3.56±0.91）、（2.82±1.16）、（19.25±13.60）、（10.10±7.26）,对照组BASDAI、BASFI评分及ESR、CRP值分别为（4.69±1.26）、（4.35±1.12）、（29.30±17.86）、（12.83±11.27）,两组间有差异（P〈0.05）,治疗组优于对照组。结论：灯盏生脉胶囊联合NSAIDs、DMARDs能有效控制AS的炎症活动。

Clinical research on treating ankylosing spondylitis with Dengzhan Shengmai capsules

Objective：To evaluate the effectiveness and safety of active ankylosing spondylitis with total Dengzhan Shengmai capsules.Methods：Eighty patients were randomly assigned to two groups,fourty cases a group,all patients were treated with the routine therapy with NSAIDs and DMARDs,But for the treatment group Dengzhan Shengmai capsules was given additionally,every time 0.36g,three times a day.The therapeutic course was 12 weeks for both groups,the observation items in-cluded symptoms and sign,and side effects have been used to assess.Results：Treatment group was 87.18% and the control group 75.68% （P0.05） have significant difference,after 12 weeks,the BASDAI,BASFI scores and ESR,CRP of treatment group were （3.56±0.91）,（2.82±1.16）,（19.25±13.60）,（10.10±7.26）;The BASDAI,BASFI scores and ESR,CRP of control group were （4.69±1.26）,（4.35±1.12）,（29.30±17.86）,（12.83±11.27）,the differences between the two groups （P0.05） were that treatment group was superior to control group.Conclusion：Dengzhan Shengmai capsules can control the inflammatione of AS effectively.